U.S. Genomics Expands its Efforts With New VP
News Sep 30, 2005
U.S. Genomics has announced that Dr. Duncan Whitney joined the Company's management team as Vice President of Research and Development.
Dr. Whitney will spearhead existing efforts in the Company's single molecule technology, which directly detects and quantitates individual molecules of miRNA, DNA, RNA, and proteins without the need for amplification.
“Duncan brings significant scientific and product development experience to the Company,” said John J. Canepa, acting Chief Executive Officer of U.S. Genomics.
“Duncan will play a key role in the development of additional applications for the Trilogy 2020 platform as we accelerate our commercialization efforts.”
“Duncan's success in driving research and development at EXACT Sciences Corporation and other emerging life science companies makes him an excellent addition to our team.”
Prior to joining U.S. Genomics, Dr. Whitney served as Vice President of Technology for EXACT Sciences developing DNA diagnostic assays for cancer screening.
“U.S. Genomics' technology has the potential to revolutionize how scientists perform life science research and I look forward to utilizing my experience at U.S. Genomics to make this technology widely available,” said Dr. Whitney.
China is poised to introduce a new regulation on gene editing in humans. A draft of the country’s new civil code lists human genes and embryos in a section on personality rights to be protected. Experiments on genes in adults or embryos that endanger human health or violate ethical norms can accordingly be seen as a violation of a person’s fundamental rights.READ MORE